The DOI matches its Crossref record; 52 of the 54 references it cites were found in a registry or an index.
Somatic mutations affect key pathways in lung adenocarcinoma
Open accessAbstract
Determining the genetic basis of cancer requires comprehensive analyses of large collections of histopathologically well-classified primary tumours. Here we report the results of a collaborative study to discover somatic mutations in 188 human lung adenocarcinomas. DNA sequencing of 623 genes with known or potential relationships to cancer revealed more than 1,000 somatic mutations across the samples. Our analysis identified 26 genes that are mutated at significantly high frequencies and thus are probably involved in carcinogenesis. The frequently mutated genes include tyrosine kinases, among them the EGFR homologue ERBB4; multiple ephrin receptor genes, notably EPHA3; vascular endothelial growth factor receptor KDR; and NTRK genes. These data provide evidence of somatic mutations in primary lung adenocarcinoma for several tumour suppressor genes involved in other cancers--including NF1, APC, RB1 and ATM--and for sequence changes in PTPRD as well as the frequently deleted gene LRP1B. The observed mutational profiles correlate with clinical features, smoking status and DNA repair defects. These results are reinforced by data integration including single nucleotide polymorphism array and gene expression array. Our findings shed further light on several important signalling pathways involved in lung adenocarcinoma, and suggest new molecular targets for treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“While gain of 7p and loss of 8p have been previously reported to occur specifically in EGFR mutated adenocarcinomas16, 17, gain of 16p was a novel association.”
From Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredIn the citing paper
“KRAS mutations predominate in NSCLCs, accounting for ~78% of all RAS mutations found in such tumours17. The activating missense KRAS mutations that occur in ~25% of NSCLCs19–23 are typically mutually exclusive with other clinically actionable driver mutations, such as those in EGFR, BRAF and ALK24.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [22]
In the citing paper
“Importantly, large-scale profiling studies utilizing either whole exome sequencing or broad targeted sequencing panels in NSCLC tumors have revealed multiple non-random patterns of co-occurring or mutually exclusive mutations, which typically vary depending on the particular oncogenic driver mutation15, 34, 58–62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [60]
In the citing paper
“Activating mutations in KRAS are the most prevalent oncogenic driver event in both early-stage and metastatic LUAD, occurring in 25–32% of tumors34, 59, 60, 62, 67.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [60]
In the citing paper
“Similarly, mutations in ERBB4 were identified in cancer, particularly melanoma (Prickett et al., 2009), lung adenocarcinoma (Ding et al., 2008), and medulloblastoma (Gilbertson et al., 2001).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Ding et al., 2008
In the citing paper
“Gain/amplification of the mutant EGFR allele has previously been reported to frequently occur in LAC and is known to drive tumor progression17.”
From Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis (2019) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,077
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,710
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Self-citationEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citationEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Self-citationPao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Self-citationThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,143
Flagged first, then by citations
2 of the 54 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 801–900 of 1,007
Sachdeva, M., Sachdeva, N., Pal, M., Gupta, N., Khan, I. A., Majumdar, M., & Tiwari, A. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2015.54 · Cited by 56
Parikh, A. B., Kozuch, P. S., Rohs, N. C., Becker, D. J., & Levy, B. P. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0511-7 · Cited by 56
miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3
Zhou, Y., Dang, J., Chang, K.-Y., Yau, E., Aza-Blanc, P., Moscat, J., & Rana, T. M. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2936 · Cited by 54
Xiao, Z., Sperl, B., Ullrich, A., & Knyazev, P. G. (2014) · Oncotarget · doi:10.18632/oncotarget.2657 · Cited by 55
Valsesia, A., Rimoldi, D., Martinet, D., Ibberson, M. R., Benaglio, P., Quadroni, M., Waridel, P., Gaillard, M., Pidoux, M., Rapin, B., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018369 · Cited by 54
Naoki, K., Soejima, K., Okamoto, H., Hamamoto, J., Hida, N., Nakachi, I., Yasuda, H., Nakayama, S., Yoda, S., Satomi, R., et al. (2011) · International Journal of Clinical Oncology · doi:10.1007/s10147-011-0187-5 · Cited by 54
Mulvihill, M. S., Kwon, Y.-W., Lee, S. C. L., Fang, L. T., Choi, H., Ricchetti, R. R., Kang, H. C., Mao, J., Jablons, D. M., & Kim, I.-J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042264 · Cited by 56
CHCHD2 Is Coamplified with EGFR in NSCLC and Regulates Mitochondrial Function and Cell Migration
Wei, Y., Vellanki, R. N., Coyaud, É., Ignatchenko, V., Li, L., Krieger, J. R., Taylor, P. P., Tong, J., Pham, N., Liu, G., et al. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0165-t · Cited by 55
Brantley‐Sieders, D. M. (2011) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2011.10.014 · Cited by 57
Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy
Heinzle, C. F., Sutterlüty, H., Grusch, M., Grasl‐Kraupp, B., Berger, W., & Marian, B. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.566217 · Cited by 55
Attenuation of Eph Receptor Kinase Activation in Cancer Cells by Coexpressed Ephrin Ligands
Falivelli, G., Lisabeth, E. M., de la Torre, E. R., Pérez‐Tenorio, G., Tosato, G., Salvucci, O., & Pasquale, E. B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081445 · Cited by 58
Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years
Northcott, P. A., Rutka, J. T., & Taylor, M. D. (2009) · Neurosurgical FOCUS · doi:10.3171/2009.10.focus09218 · Cited by 54
Jiang, B., Zhang, X., Su, J., Meng, W., Yang, X., Yang, J., Zhou, Q., Chen, Z., Chen, Z., Xie, Z., et al. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-61 · Cited by 55
Lessons from a decade of integrating cancer copy number alterations with gene expression profiles
Huang, N., Shah, P. K., & Li, C. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr056 · Cited by 57
Sample-level enrichment analysis unravels shared stress phenotypes among multiple cancer types
Gundem, G., & López-Bigas, N. (2012) · Genome Medicine · doi:10.1186/gm327 · Cited by 52
Ayoola, A., Barochia, A., Belani, K., & Belani, C. P. (2012) · Cancer Investigation · doi:10.3109/07357907.2012.666691 · Cited by 56
Lung Squamous Cell Carcinomas with Basaloid Histology Represent a Specific Molecular Entity
Brambilla, C., Laffaire, J., Lantuéjoul, S., Moro‐Sibilot, D., Nagy-Mignotte, H., Arbib, F., Toffart, A., Petel, F. X., Hainaut, P. L., Rousseaux, S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0459 · Cited by 55
Li, C., Gao, Z., Li, F., Li, X., Sun, Y., Wang, M., Li, D., Wang, R., Li, F., Fang, R., et al. (2015) · Scientific Reports · doi:10.1038/srep14237 · Cited by 56
Zhang, J., Feng, S., Su, W., Bai, S., Xiao, L., Wang, L., Thomas, D. G., Lin, J., Reddy, R. M., Carrott, P. W., et al. (2017) · Scientific Reports · doi:10.1038/srep42819 · Cited by 55
Self-citationFoy, V., Schenk, M. W., Baker, K., Gomes, F., Lallo, A., Frese, K. K., Forster, M. D., Dive, C., & Blackhall, F. H. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.10.006 · Cited by 54
Genomic Underpinnings of Tumor Behavior in In Situ and Early Lung Adenocarcinoma
Qian, J., Zhao, S., Zou, Y., Rahman, S. M. J., Senosain, M.-F., Stricker, T. P., Chen, H., Powell, C. A., Borczuk, A., & Massion, P. P. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201902-0294oc · Cited by 55
Genetic basis of tumorigenesis in NF1 malignant peripheral nerve sheath tumors
Upadhyaya, M. (2010) · Frontiers in bioscience · doi:10.2741/3727 · Cited by 54
Neurofibromatosis type 1 and associated malignancies
Yohay, K. H. (2009) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-009-0036-3 · Cited by 54
Liang, M.-C., Ma, J., Chen, L., Kozłowski, P., Qin, W., Li, D. D., Goto, J., Shimamura, T., Hayes, D. N., Meyerson, M. M., et al. (2009) · Oncogene · doi:10.1038/onc.2009.452 · Cited by 54
Self-citationHayashi, T., Kumasaka, T., Mitani, K., Yao, T., Suda, K., & Seyama, K. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.114 · Cited by 54
GNAS codon 201 mutations are uncommon in intraductal papillary neoplasms of the bile duct
Matthaei, H., Wu, J., Molin, M. D., Debeljak, M., Lingohr, P., Katabi, N., Klimstra, D. S., Adsay, V. N., Eshleman, J. R., Schulick, R. D., et al. (2012) · HPB · doi:10.1111/j.1477-2574.2012.00504.x · Cited by 54
Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma
Go, H., Jung, Y. J., Kang, H. W., Park, I. K., Kang, C. H., Lee, J. W., Ju, Y. S., Seo, J., Chung, D. H., & Kim, Y. T. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.07.009 · Cited by 54
Nrf2 and Notch Signaling in Lung Cancer: Near the Crossroad
Sparaneo, A., Fabrizio, F. P., & Muscarella, L. A. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/7316492 · Cited by 54
Dubey, S., & Powell, C. A. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200902-0289up · Cited by 54
Ricciuti, B., Genova, C., Crinò, L., Libra, M., & Leonardi, G. C. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s177051 · Cited by 54
Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells
Lee, W., Lee, J. H., Jun, S., Lee, J. H., & Bang, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-30205-2 · Cited by 53
Bonanno, L., De Paoli, A., Zulato, E., Esposito, G., Calabrese, F., Favaretto, A., Santo, A., Conte, A. D., Chilosi, M., Oniga, F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2410 · Cited by 53
Mouse Tumor Biology (MTB): a database of mouse models for human cancer
Bult, C. J., Krupke, D. M., Begley, D. A., Richardson, J. E., Neuhauser, S. B., Sundberg, J. P., & Eppig, J. T. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku987 · Cited by 55
Rein, I. D., Landsverk, K. S., Micci, F., Patzke, S., & Stokke, T. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1085137 · Cited by 54
The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma
Villaruz, L. C., Socinski, M. A., Cunningham, D. E., Chiosea, S. I., Burns, T. F., Siegfried, J. M., & Đačić, S. (2013) · Cancer · doi:10.1002/cncr.28039 · Cited by 53
McGrail, M. A., Hatler, J. M., Kuang, X., Liao, H.-K., Nannapaneni, K., Watt, K. E. N., Uhl, J. D., Largaespada, D. A., Vollbrecht, E., Scheetz, T. E., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018826 · Cited by 53
Image-guided radiotherapy platform using single nodule conditional lung cancer mouse models
Herter-Sprie, G. S., Korideck, H., Christensen, C. L., Herter, J. M., Rhee, K., Berbeco, R. I., Bennett, D. G., Akbay, E. A., Kozono, D., Mak, R. H., et al. (2014) · Nature Communications · doi:10.1038/ncomms6870 · Cited by 52
Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas
Kim, I.-J., Quigley, D. A., To, M. D., Pham, P., Lin, K., Jo, B., Jen, K., Raz, D. J., Kim, J. H., Mao, J., et al. (2013) · Nature Communications · doi:10.1038/ncomms2660 · Cited by 52
The Landscape of EGFR Pathways and Personalized Management of Non-Small-Cell Lung Cancer
Liang Cheng, C., Zhang, S., Alexander, R. E., Yao, Y., MacLennan, G. T., Pan, C.-X., Huang, J., Wang, M., Montironi, R., & Antonio Lopez-beltran, B. (2011) · Future Oncology · doi:10.2217/fon.11.25 · Cited by 53
Yin, Y., Betsuyaku, T., Garbow, J. R., Miao, J., Govindan, R., & Ornitz, D. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0495 · Cited by 53
Saab, J., Zia, H. M., Mathew, S., Kluk, M., Narula, N., & Fernandes, H. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.02.009 · Cited by 53
Protein kinase LKB1 promotes RAB7-mediated neuropilin-1 degradation to inhibit angiogenesis
Okon, I. S., Coughlan, K. A., Zhang, C., Moriasi, C., Ding, Y., Song, P., Zhang, W., Li, G., & Zou, M.-H. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75371 · Cited by 52
Arnedos, M., Vielh, P. R., Soria, J., & André, F. (2013) · The Journal of Pathology · doi:10.1002/path.4276 · Cited by 51
Lawal, B., Lee, C., Mokgautsi, N., Sumitra, M. R., Khedkar, H., Wu, A. T. H., & Huang, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.656738 · Cited by 52
TSC1 involvement in bladder cancer: diverse effects and therapeutic implications
Guo, Y., Chekaluk, Y. I., Zhang, J., Du, J., Gray, N. S., Wu, C., & Kwiatkowski, D. J. (2013) · The Journal of Pathology · doi:10.1002/path.4176 · Cited by 54
YB ‐1 promotes transcription of cyclin D1 in human non‐small‐cell lung cancers
Harada, M., Kotake, Y., Ohhata, T., Kitagawa, K., Niida, H., Matsuura, S., Funai, K., Sugimura, H., Suda, T., & Kitagawa, M. (2014) · Genes to Cells · doi:10.1111/gtc.12150 · Cited by 53
Ummanni, R., Mannsperger, H., Sonntag, J., Oswald, M., Sharma, A. K., König, R., & Korf, U. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2013.11.017 · Cited by 53
Sun, Z., Wang, Z., Liu, X., & Wang, D. (2014) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000172 · Cited by 53
Fustaino, V., Presutti, D., Colombo, T., Cardinali, B., Papoff, G., Brandi, R., Bertolazzi, P., Felici, G., & Ruberti, G. (2017) · Oncotarget · doi:10.18632/oncotarget.21132 · Cited by 52
Karagiannakos, A., Adamaki, M., Tsintarakis, A., Vojtěšek, B., Fåhræus, R., Zoumpourlis, V. C., & Karakostis, K. (2022) · Cancers · doi:10.3390/cancers14030664 · Cited by 59
Almeida, M. Q., Harran, M. D., Bimpaki, E. I., Hsiao, H., Horvath, A., Cheadle, C., Watkins, T., Nesterova, M., & Stratakis, C. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2420 · Cited by 51
Regulation of Tumor Initiation and Metastatic Progression by Eph Receptor Tyrosine Kinases
Chen, J. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-386503-8.00001-6 · Cited by 51
Upadhyaya, M., Spurlock, G., Thomas, L. E., Thomas, N. S. T., Richards, M., Mautner, V.-F., Cooper, D. N., Guha, A., & Yan, J. S. (2012) · Human Mutation · doi:10.1002/humu.22044 · Cited by 51
Receptor Tyrosine Kinase EphA5 Is a Functional Molecular Target in Human Lung Cancer
Staquicini, F. I., Qian, M. D., Salameh, A., Dobroff, A. S., Edwards, J. K., Cimino, D. F., Moeller, B. J., Kelly, P., Nunez, M. I., Tang, X., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.630525 · Cited by 52
Self-citationInhibition and Termination of Physiological Responses by GTPase Activating Proteins
Ligeti, E., Welti, S., & Scheffzek, K. (2012) · Physiological Reviews · doi:10.1152/physrev.00045.2010 · Cited by 61
Chuang, C.-H., Dorsch, M., Dujardin, P., Silas, S., Ueffing, K., Hölken, J. M., Yang, D., Winslow, M. M., & Grüner, B. M. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1865 · Cited by 55
Comprehensive Mapping of the Human Kinome to Epidermal Growth Factor Receptor Signaling
Komurov, K., Padrón, D., Cheng, T., Roth, M. G., Rosenblatt, K. P., & White, M. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.137828 · Cited by 50
The BATTLE to Personalize Lung Cancer Prevention through Reverse Migration
Gold, K. A., Kim, E. S., Lee, J. J., Wistuba, I. I., Farhangfar, C. J., & Hong, W. K. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0232 · Cited by 51
Self-citationKline, E. R., Shupe, J. A., Gilbert‐Ross, M., Zhou, W., & Marcus, A. I. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.444620 · Cited by 48
LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor
Gao, Y., Ge, G., & Ji, H. (2011) · Protein & Cell · doi:10.1007/s13238-011-1021-6 · Cited by 50
Genetic and Biochemical Alterations in Non-Small Cell Lung Cancer
Johnson, J. L., Pillai, S., & Chellappan, S. (2012) · Biochemistry Research International · doi:10.1155/2012/940405 · Cited by 52
Unraveling Tumor Grading and Genomic Landscape in Lung Neuroendocrine Tumors
Pelosi, G., Papotti, M. G., Rindi, G., & Scarpa, A. (2014) · Endocrine Pathology · doi:10.1007/s12022-014-9320-0 · Cited by 49
Extracting consistent knowledge from highly inconsistent cancer gene data sources
Gong, X., Wu, R., Zhang, Y., Zhao, W., Cheng, L., Gu, Y., Zhang, L., Wang, J., Zhu, J., & Guo, Z. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-76 · Cited by 50
KRAS mutant allele-specific imbalance in lung adenocarcinoma
Chiosea, S. I., Sherer, C., Jelic, T. M., & Đačić, S. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.109 · Cited by 50
The FGF/FGF receptor axis as a therapeutic target in breast cancer
Brady, N. J., Chuntova, P., Bade, L. K., & Schwertfeger, K. L. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2013.811910 · Cited by 51
Maramotti, S., Paci, M., Manzotti, G., Rapicetta, C., Gugnoni, M., Galeone, C., Cesario, A., & Lococo, F. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040593 · Cited by 47
Vinayanuwattikun, C., Calvez‐Kelm, F. L., Abedi‐Ardekani, B., Zaridze, D. G., Mukeria, A., Voegele, C., Vallée, M., Purnomosari, D., Forey, N., Durand, G., et al. (2016) · Scientific Reports · doi:10.1038/srep31628 · Cited by 49
Pritchett, M. A., Camidge, D. R., Patel, M., Khatri, J., Boniol, S., Friedman, E. K., Khomani, A., Dalia, S. M., Baker-Neblett, K. L., Plagnol, V., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00299 · Cited by 50
Jette, N., Radhamani, S., Arthur, G., Ye, R., Goutam, S., Bolyos, A., Petersen, L. F., Bose, P., Bebb, D. G., & Lees‐Miller, S. P. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0565-8 · Cited by 50
Key characteristics of 86 agents known to cause cancer in humans
Krewski, D. R., Bird, M. G., Al‐Zoughool, M., Birkett, N., Billard, M., Milton, B., Rice, J. M., Grosse, Y., Cogliano, V. J., Hill, M. A., et al. (2019) · Journal of Toxicology and Environmental Health Part B · doi:10.1080/10937404.2019.1643536 · Cited by 51
Li, T., Yu, Y., Song, Y., Li, X., Lan, D., Zhang, P., Xiao, Y., & Xing, Y. (2020) · The FASEB Journal · doi:10.1096/fj.201802159rrr · Cited by 50
Ezponda, T., Pajares, M. J., Agorreta, J., Echeveste, J. I., López-Picazo, J. M., Torre, W., Pı́o, R., & Montuenga, L. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0076 · Cited by 55
Regulation of Autophagy via Carbohydrate and Lipid Metabolism in Cancer
Alizadeh, J., Kavoosi, M., Singh, N., Lorzadeh, S., Ravandi, A., Kidane, B., Ahmed, N., Mraiche, F., Mowat, M. R. A., & Ghavami, S. (2023) · Cancers · doi:10.3390/cancers15082195 · Cited by 51
Inferring the functional effects of mutation through clusters of mutations in homologous proteins
Yue, P., Forrest, W. F., Kaminker, J. S., Lohr, S., Zhang, Z., & Cavet, G. (2010) · Human Mutation · doi:10.1002/humu.21194 · Cited by 49
Guidance molecules in lung cancer
Nasarre, P., Potiron, V. A., Drabkin, H. A., & Roche, J. (2010) · Cell Adhesion & Migration · doi:10.4161/cam.4.1.10882 · Cited by 49
Nashed, M., Chisholm, J. W., & Igal, R. A. (2012) · Experimental Biology and Medicine · doi:10.1258/ebm.2012.012126 · Cited by 50
Evaluation of Kras Gene Mutation and Copy Number Gain in Non-small Cell Lung Cancer
Sasaki, H., Hikosaka, Y., Kawano, O., Moriyama, S., Yano, M., & Fujii, Y. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31820594f0 · Cited by 49
Inhibition of PI-3K restores nuclear p27Kip1 expression in a mouse model of Kras-driven lung cancer
Kelly‐Spratt, K. S., Staheli, J. P., Gurley, K. E., Hoon-Kim, K., Knoblaugh, S. E., & Kemp, C. J. (2009) · Oncogene · doi:10.1038/onc.2009.226 · Cited by 49
Coco, S., Truini, A., Vanni, I., Bello, M. G. D., Alama, A., Rijavec, E., Genova, C., Barletta, G., Sini, C., Burrafato, G., et al. (2014) · Current Drug Targets · doi:10.2174/1389450116666141210094640 · Cited by 51
Araujo, L. H., Timmers, C. D., Bell, E. H., Shilo, K., Lammers, P. E., Zhao, W., Natarajan, T. G., Miller, C. J., Zhang, J., Yilmaz, A. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.2444 · Cited by 48
Predictive biomarkers in precision medicine and drug development against lung cancer
Fang, B., Mehran, R. J., Heymach, J. V., & Swisher, S. G. (2015) · 癌症：英文版 · doi:10.1186/s40880-015-0028-4 · Cited by 49
A Novel Role for hSMG-1 in Stress Granule Formation
Brown, J. A. L., Roberts, T. L., Richards, R. S., Woods, R. G., Birrell, G. W., Lim, Y. C., Ohno, S., Yamashita, A., Abraham, R. T., Gueven, N., et al. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05987-11 · Cited by 50
Li, Y., Li, Y., Ge, P., & Ma, C. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9654-8 · Cited by 49
RetractedCanProVar 2.0: An Updated Database of Human Cancer Proteome Variation
Zhang, M., Wang, B., Xu, J., Wang, X., Xie, L., Zhang, B., Li, Y., & Li, J. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00505 · Cited by 48
Kim, H., Yang, J. M., Jin, Y., Jheon, S., Kim, K., Lee, C. T., Chung, J.-H., & Paik, J. H. (2016) · Oncotarget · doi:10.18632/oncotarget.14298 · Cited by 49
Chang, W. H., Forde, D., & Lai, A. G. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1775-9 · Cited by 47
Galka-Marciniak, P., Urbanek-Trzeciak, M. O., Nawrocka, P. M., Dutkiewicz, A., Giefing, M., Lewandowska, M. A., & Kozłowski, P. (2019) · Cancers · doi:10.3390/cancers11060793 · Cited by 49
DDR1 promotes breast tumor growth by suppressing antitumor immunity
Zhong, X., Zhang, W., & Sun, T. (2019) · Oncology Reports · doi:10.3892/or.2019.7338 · Cited by 49
A Diagnostic Panel of DNA Methylation Biomarkers for Lung Adenocarcinoma
Shen, N., Du, J., Zhou, H., Chen, N., Pan, Y., Hoheisel, J. D., Jiang, Z., Xiao, L., Tao, Y., & Mo, X. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01281 · Cited by 50
Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients
Bacchi, C. E., Ciol, H., Queiroga, E., Benine, L. C., Silva, L. H., & Ojopi, E. P. B. (2012) · Clinics · doi:10.6061/clinics/2012(05)03 · Cited by 49
Strong association between lung cancer and the AXIN2 polymorphism
Pinarbasi (2009) · Molecular Medicine Reports · doi:10.3892/mmr_00000210 · Cited by 48
Lung Cancer in Nonsmoking Individuals
Murphy, C., Pandya, T., Swanton, C., & Solomon, B. (2025) · JAMA · doi:10.1001/jama.2025.17695 · Cited by 55
Phosphorylation of FADD by the kinase CK1α promotes KRAS G12D -induced lung cancer
Bowman, B. M., Sebolt, K. A., Hoff, B. A., Boes, J. L., Daniels, D. L., Heist, K. A., Galbán, C. J., Patel, R. M., Zhang, J., Beer, D. G., et al. (2015) · Science Signaling · doi:10.1126/scisignal.2005607 · Cited by 48
Self-citationUpregulation of the microRNA cluster at the Dlk1-Dio3 locus in lung adenocarcinoma
Valdmanis, P. N., Roy‐Chaudhuri, B., Kim, H.-X., Sayles, L. C., Zheng, Y., Chuang, C.-H., Caswell, D. R., Chu, K. P.-M., Zhang, Y., Winslow, M. M., et al. (2013) · Oncogene · doi:10.1038/onc.2013.523 · Cited by 49
Data mining using the Catalogue of Somatic Mutations in Cancer BioMart
Shepherd, R., Forbes, S. A., Beare, D. M., Bamford, S., Cole, C. G., Ward, S., Bindal, N., Gunasekaran, P., Jia, M., Kok, C. Y., et al. (2011) · Database · doi:10.1093/database/bar018 · Cited by 48
Nagel, I., Szczepanowski, M., Martín-Subero, J. I., Harder, L., Akasaka, T., Ammerpohl, O., Callet‐Bauchu, E., Gascoyne, R. D., Gesk, S., Horsman, D. E., et al. (2010) · Blood · doi:10.1182/blood-2009-09-240440 · Cited by 48
Effects of tobacco smoking on HIV-infected individuals.
Calvo, M., Laguno, M., Martínez, M., & Martínez, E. (2015) · PubMed · Cited by 48
The CREB coactivator CRTC2 promotes oncogenesis in LKB1-mutant non–small cell lung cancer
Rodón, L., Svensson, R. U., Wiater, E., Chun, M. G. H., Tsai, W., Eichner, L. J., Shaw, R. J., & Montminy, M. (2019) · Science Advances · doi:10.1126/sciadv.aaw6455 · Cited by 50
Progress in Neoantigen Targeted Cancer Immunotherapies
Han, X., Ma, X., Li, Y., Wei, Y.-Q., Peng, Y., & Wei, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00728 · Cited by 49
Evaluating the transcriptional fidelity of cancer models
Peng, D., Gleyzer, R., Tai, W.-H., Kumar, P., Bian, Q., Isaacs, B., da Rocha, E. L., Cai, S., DiNapoli, K. T., Huang, F. W., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00888-w · Cited by 48
Metadata
- Authors
- Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., Fulton, L., Fulton, R. S., Zhang, Q., Wendl, M. C., Lawrence, M. S., Larson, D. E., Chen, K., Dooling, D. J., Sabo, A., Hawes, A. C., Shen, H., Jhangiani, S. N., Lewis, L. R., Hall, O., Zhu, Y., Mathew, T., Ren, Y., Yao, J., Scherer, S. E., Clerc, K., Metcalf, G. A., Ng, B., Milosavljevic, A., Gonzalez-Garay, M. L., Osborne, J. R., Meyer, R., Shi, X., Tang, Y., Koboldt, D. C., Lin, L., Abbott, R., Miner, T. L., Pohl, C., Fewell, G., Haipek, C., Schmidt, H., Dunford-Shore, B. H., Kraja, A., Crosby, S. D., Sawyer, C. S., Vickery, T., Sander, S., Robinson, J., Winckler, W., Baldwin, J., Chirieac, L. R., Dutt, A., Fennell, T., Hanna, M., Johnson, B. E., Onofrio, R. C., Thomas, R. K., Tonon, G., Weir, B. A., Zhao, X., Ziaugra, L., Zody, M. C., Giordano, T., Orringer, M. B., Roth, J. A., Spitz, M. R., Wistuba, I. I., Ozenberger, B., Good, P. J., Chang, A. C., Beer, D. G., Watson, M. A., Ladanyi, M., Broderick, S., Yoshizawa, A., Travis, W. D., Pao, W., Province, M. A., Weinstock, G. M., Varmus, H. E., Gabriel, S. B., Lander, E. S., Gibbs, R. A., Meyerson, M., & Wilson, R. K.
- Affiliations
- Washington University in St. Louis (US)
- Broad Institute (US)
- Baylor College of Medicine (US)
- Brigham and Women's Hospital (US)
- Dana-Farber Cancer Institute (US)
- Max Planck Society (DE)
- University of Michigan (US)
- The University of Texas MD Anderson Cancer Center (US)
- National Institutes of Health (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Meyerson, Matthew
- Wilson, Richard K.
- ORCID
- Ding, Li
- Getz, Gad
- Wheeler, David A.
- Mardis, Elaine R.
- McLellan, Michael D.
- Cibulskis, Kristian
- Greulich, Heidi
- Muzny, Donna M.
- Morgan, Margaret B.
- Fulton, Lucinda
- Fulton, Robert S.
- Wendl, Michael C.
- Lawrence, Michael S.
- Larson, David E.
- Chen, Ken
- Sabo, Aniko
- Shen, Hua
- Jhangiani, Shalini N.
- Zhu, Yiming
- Ren, Yanru
- Yao, Jiqiang
- Scherer, Steven E.
- Metcalf, Ginger A.
- Ng, Brian
- Milosavljevic, Aleksandar
- Tang, Yuzhu
- Koboldt, Daniel C.
- Lin, Ling
- Pohl, Craig
- Crosby, Seth D.
- Vickery, Tammi
- Winckler, Wendy
- Chirieac, Lucian R.
- Dutt, Amit
- Fennell, Tim
- Johnson, Bruce E.
- Thomas, Roman K.
- Tonon, Giovanni
- Zody, Michael C.
- Giordano, Thomas
- Roth, Jack A.
- Wistuba, Ignacio I.
- Ozenberger, Bradley
- Chang, Andrew C.
- Beer, David G.
- Watson, Mark A.
- Ladanyi, Marc
- Broderick, Stephen
- Yoshizawa, Akihiko
- Travis, William D.
- Pao, William
- Province, Michael A.
- Weinstock, George M.
- Varmus, Harold E.
- Gabriel, Stacey B.
- Lander, Eric S.
- Gibbs, Richard A.
- Meyerson, Matthew
- Wilson, Richard K.
- Venue
- Nature
- Published
- 2008-10
- Volume
- 455
- Issue
- 7216
- Pages
- 1069-1075
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2694412
- OpenAlex
- W2163798887
- Cited by
- 2,681
- References
- 54
- Citations by year
- 2026: 21 · 2025: 48 · 2024: 53 · 2023: 122 · 2022: 124 · 2021: 149 · 2020: 147 · 2019: 145 · 2018: 121 · 2017: 141 · 2016: 158 · 2015: 206 · 2014: 254 · 2013: 213 · 2012: 227
- FWCI
- 167.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Max Planck Institute for Plasma Physics (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Broad Institute
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (U19CA084953, P50CA070907, R01CA154365)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung adenocarcinoma, somatic mutations, carcinogenesis, tyrosine kinase, EphA3, Eph receptors, KDR, NTRK, tumor suppressor, neurofibromatosis type 1, APC, RB1, ATM, PTPRD, LRP1B, smoking, DNA repair deficiency, signaling pathways, molecular targets, mutational landscape
- MeSH terms
- Adenocarcinoma, Bronchiolo-Alveolar, Female, Humans, Lung Neoplasms, Male, Mutation, Proto-Oncogenes, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Gene Dosage
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
